Video Experimental Relacionado
Updated: Jan 13, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.2K
Cilostazol en un niño con enfermedad de Moyamoya
Alizah A Patterson1,2, Sarah K D Vogel2, April Sharp1,2
1Department of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, MD, USA.
Journal of child neurology
|January 8, 2026
Resumen
El cilostazol puede ser un tratamiento seguro y eficaz para la enfermedad de Moyamoya pediátrica, una rara afección cerebrovascular. Se necesita más investigación para confirmar sus beneficios en niños con enfermedad de Moyamoya.
Área de la Ciencia:
- Neurología; Neurología Pediátrica; Enfermedades Cerebrovasculares
Sus antecedentes:
- La enfermedad de Moyamoya implica estenosis progresiva de las arterias carótidas, lo que conduce a riesgo de accidente cerebrovascular.; La revascularización quirúrgica es común, pero la evidencia de intervenciones no quirúrgicas en niños es limitada.; El cilostazol muestra promesa en adultos, pero su uso pediátrico no está probado.
Objetivo del estudio:
- Evaluar la seguridad y eficacia del cilostazol en un paciente pediátrico con enfermedad de Moyamoya.; Explorar opciones de manejo no quirúrgico para eventos neurológicos transitorios en la enfermedad de Moyamoya pediátrica.
Principales métodos:
- Reporte de caso de una niña de 9 años con enfermedad de Moyamoya.; Eventos neurológicos transitorios documentados después de la sinangiosis pial.; Se evaluó el impacto del cilostazol en la frecuencia y gravedad de los eventos después de que otros tratamientos fallaron.
Principales resultados:
- El paciente experimentó eventos neurológicos transitorios frecuentes, que incluyeron disartria y caída facial.; Los medicamentos anticonvulsivos y la potenciación de la presión arterial fueron ineficaces.; La administración de cilostazol condujo a la disminución de los eventos, con recurrencia y resolución tras el ajuste de la dosis.
Conclusiones:
- Este caso sugiere que el cilostazol puede ser una opción segura y eficaz para el manejo de la enfermedad de Moyamoya pediátrica.; Se requieren más ensayos clínicos para establecer el papel del cilostazol en el tratamiento de la enfermedad de Moyamoya pediátrica.; El cilostazol ofrece una vía terapéutica no quirúrgica potencial para pacientes pediátricos con Moyamoya que experimentan eventos neurológicos recurrentes.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:26Mitral Stenosis III: Medical Management
239
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
239
01:27Peripheral Artery Disease III: Interprofessional Care
236
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
236
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
429
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
429
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452
01:29Drug Dosing: Infants and Children
248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189